Dr. Lewin, Chairman, National Coalition on Health Care applauds @VIMCollab's Action Plan:
"We know VBAs benefit innovators, payers, and most importantly patients, and I hope this roadmap serves to spark the change we need to allow a more favorable environment to support VBAs."
In our recent briefing with @NC_HC, Dr. Fred Ledley, the director of the Center for Integration of Science and Industry at Bentley University, and a former biotechnology entrepreneur and CEO spoke about the findings.
View the full report here: https://t.co/pys2T653Rb
Today, 11:15am ET: President Biden lays out elements of his plan to lower Rx drug costs as a key feature of the Build Back Better plan. He calls on Congress to act. @POTUS is listening to the powerful voices of patient advocates. He really understands.
https://t.co/l7YBhRBigK
With 52.7% of #MedicareAdvantage beneficiaries living below 200% of the Federal Poverty Level, policy solutions to address social determinants of health are more important than ever. A new report from @BMAlliance Offers a way forward. https://t.co/2rBwIvoz6E
Thanks for the quote @BLaw from our @WestHealth@NC_HC event last week on #Drug Pricing Reform: The Costs of Inaction. "We want to make sure that any changes that happen will affect people in the commercial market as well as people in the Medicare program" https://t.co/Q28ZDPgpto
Honored to join @NC_HC & @WestHealth for Congressional Briefing to discuss evidence that reducing drug prices could inhibit @innovation and new research from @SciIndustry@BentleyU that this may be mitigated by #agile management. Recording now available: https://t.co/TlUrvT6ZC8
Broad and bipartisan support for government action to lower drug prices. Discussed during recent briefing with @NC_HC and reported via @InHealthPolicy. https://t.co/XhQiSn7JzU
@sgremminger, Director of Health Policy, @PBGHealth shares recommendations regarding the cost of #healthcare which include:
👉Having Medicare negotiate the price of drugs
👉Capping prices of drugs currently on the market
👉Restructuring Medicare Part D to reduce overall costs
Research from @SciIndustry, @bentleyu finds that small companies have an important role in new #drugdevelopment; data shows small companies conduct about 60% of all clinical trials.
It's not just bipartisan, it's beneficial for all of us," Congressman @PeterWelch emphasized regarding lowering the cost of healthcare and the biggest driver, the escalation of #prescriptiondrug prices.
[@WestHealth, @iamamyherr]
We are grateful to hear remarks from Congressman @PeterWelch during today's briefing.
He spoke to the role of pharmaceutical companies in accessing prescription drugs, the recent #alzheimersdrug, and healthcare affordability at large.
Did you know that 34 million people know someone who has died due to not being able to afford their care?
Participants heard results from a recent study conducted by @WestHealth and @Gallup that included this striking statistic among others. [@iamamyherr]
🚨New speaker announcement!🚨 We are honored to have Congresswoman @ElissaSlotkin join us to provide closing remarks at our briefing on the costs of inaction for #DrugPricingReform w/ @WestHealth on July 28. Register now!
https://t.co/chsljT7zvI